Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026
Source: SeekingAlpha
2026-05-12 17:19:08 ET
The last time I spoke about Fate Therapeutics, Inc. ( FATE ), it was with a Seeking Alpha article entitled " Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options ." With respect to this article, I mentioned that it was able to achieve positive data from 1 patient from the phase 1 study with moderate-to-severe systemic lupus erythematosus [SLE]. In essence, with a 6-month follow-up period, this single patient was remission-free. I had a "Strong Buy" rating at that time, but now I'm going to change the rating to a "Hold."...
Read the full article on Seeking Alpha
For further details see:
Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026
Fate Therapeutics Inc.
NASDAQ: FATE
FATE Trading
8.84% G/L:
$2.0036 Last:
2,301,386 Volume:
$2.02 Open:
FATE Latest News
May 13, 2026 08:30:00 am
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
May 11, 2026 08:30:00 am
Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting
FATE Stock Data
$128,041,041
108,996,378
1.54%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
